Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital has reached the halfway mark. Preliminary imaging data from the study show encouraging signals in acute MS lesions and potential sensitivity to gray matter lesions, according to the company's press release. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, a hallmark of MS.
Quantum believes this imaging approach could enhance the development of MS therapies, including its investigational candidate Lucid-MS. The company submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the U.S. Food and Drug Administration in March 2026. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The ability to directly visualize demyelination with PET imaging could provide a more sensitive biomarker for assessing treatment efficacy in clinical trials.
The study's focus on gray matter lesions is particularly noteworthy, as these lesions are associated with disability progression in MS and are often missed by conventional MRI. If the [¹⁸F]3F4AP tracer proves effective in detecting gray matter demyelination, it could become a valuable tool for both diagnosis and monitoring of disease progression. The full press release is available at https://ibn.fm/4IZ0y.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is focused on research and development of Lucid-MS. Additionally, Quantum invented UNBUZZD(TM) and retains a 19.84% ownership stake in Unbuzzd Wellness Inc., along with royalty payments from sales of UNBUZZD. The company's newsroom provides further updates at https://ibn.fm/QNTM.
The achievement of midpoint enrollment marks a significant step forward in validating the imaging technique. If successful, this study could not only accelerate the development of Lucid-MS but also provide a more precise tool for evaluating other demyelinating therapies. The implications for MS patients are substantial, as better imaging could lead to earlier diagnosis and more targeted treatments.
